论文部分内容阅读
目的:探讨DCs-CIK细胞免疫(Dendritic cells-Cytokine induced killer cells,DCs-CIK)治疗联合化疗对转移性前列腺癌患者免疫功能及生活质量的影响。方法:选择106例确诊转移性前列腺癌患者随机分为观察组与对照组,每组各53例,对照组采用多西他赛联合表阿霉素~+泼尼松化疗方式进行治疗,观察组在此基础上给予DC-CIK细胞免疫治疗。比较两组患者治疗前后外周血CD3~+、CD3~+CD4~+、CD3~+CD8~+、CD3-CD56~+、CD4~+CD8~+、自然杀伤细胞(NK)、自然杀伤T细胞(NKT)表达水平;使用QLQ-C30问卷评价患者治疗前后生活质量的变化情况,观察并比较患者治疗过程中发生的不良反应情况。结果:组观察组患者治疗总有效率达73.58%远高于对照组41.51%水平(p<0.05);观察组患者治疗后外周血CD3~+、CD3~+CD4~+、CD3~+CD8~+、CD3-CD56~+、CD4~+CD8~+、NK、NKT表达水平明显好于对照组(p<0.05);观察组患者躯体功能、角色功能、情绪功能、认知功能、社会功能各项指标得分明显好于对照组(p<0.05);两组患者接受治疗后,均有部分患者出现恶心呕吐、脱发、白细胞减少、血小板减少或肝功受损,其中观察组患者出现恶心呕吐、白细胞减少的人数明显少于对照组(p<0.05)。结论:DCs-CIK细胞免疫治疗联合化疗有助于转移性前列腺癌患者的治疗,在明显改善患者免疫能力的同时有效改善患者生活质量,具有重要的临床指导意义。
Objective: To investigate the effect of dendritic cells-Cytokine induced killer cells (DCs-CIK) combined with chemotherapy on immune function and quality of life in patients with metastatic prostate cancer. Methods: A total of 106 patients with metastatic prostate cancer who were diagnosed as metastatic prostate cancer were randomly divided into observation group and control group, with 53 patients in each group. The control group was treated with docetaxel and epirubicin plus prednisone. The observation group On this basis, DC-CIK cell immunotherapy was given. The levels of CD3 ~ +, CD3 ~ + CD4 ~ +, CD3 ~ + CD8 ~ +, CD3 ~ CD56 ~ +, CD4 ~ + CD8 ~ +, NK cells, natural killer T cells (NKT). QLQ-C30 questionnaire was used to evaluate the quality of life of patients before and after treatment. The adverse reactions during treatment were observed and compared. Results: The total effective rate of observation group was 73.58%, which was significantly higher than that of control group (41.51%, p <0.05). The levels of CD3 ~ +, CD3 ~ + CD4 ~ +, CD3 ~ + CD8 ~ CD3 + CD56 +, CD4 + CD8 +, NK and NKT in the observation group were significantly higher than those in the control group (p <0.05). The body function, role function, emotion function, cognitive function and social function Item index score was significantly better than the control group (p <0.05); two groups of patients receiving treatment, all patients had nausea and vomiting, hair loss, leukopenia, thrombocytopenia or liver damage, including observation group patients with nausea and vomiting, The number of leukopenia was significantly less than that of the control group (p <0.05). Conclusion: DCs-CIK cell immunotherapy combined with chemotherapy is helpful for the treatment of patients with metastatic prostate cancer. It is of great clinical significance in improving the patients’ quality of life while significantly improving the immunocompetence of patients.